• Explore /
  • Poster
  • / Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.

Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.

Abstract Poster

Authors

null

Huiyan Luo

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Huiyan Luo , Jin Lu , Yuxian Bai , Teng Mao , Jun Wang , Qingxia Fan , Yiping Zhang , Kuaile Zhao , Zhendong Chen , Shegan Gao , Jiancheng Li , Zhichao Fu , Kangsheng Gu , Zhihua Liu , Lin Wu , Xiaodong Zhang , Jifeng Feng , Zhen Sheng , Wanqin Zeng , Rui-Hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03691090

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4055)

DOI

10.1200/JCO.2024.42.16_suppl.4055

Abstract #

4055

Poster Bd #

35

Abstract Disclosures

Similar Posters

First Author: Xiaofeng Cong

First Author: Chen Zhang

First Author: Zhongjie Chen

First Author: Renquan Zhang